Katiravir is an HIV-1 integrase chain transfer inhibitor (INSTI) that inhibits the activity of HIV integrase, blocks the integration of viral DNA into the host cell genome, and suppresses HIV-1 replication.

1、 Drug name

1. Common name: Cabotegravir

2. Product Name: VOCARBRIA (Oral Tablets)

2、 Indications

1. HIV-1 treatment: Used in combination with EDURENT for adults and adolescents aged 12 and above, weighing ≥ 35kg, as a short-term oral therapy, suitable for HIV-1 infected individuals with virological suppression (HIV-1 RNA<50 copies/mL), no history of treatment failure, and no risk of drug resistance. It can be used as an oral infusion therapy before CABENUVA injection, or as a substitute for missed injection doses.

2. Pre exposure prophylaxis for HIV-1: Used for adults and adolescents weighing ≥ 35kg to reduce the risk of sexually transmitted HIV-1 infection. Before use, it is necessary to confirm HIV-1 negativity. It can be used as an oral introduction therapy before APRETUDE injection, or as a substitute for missed injection doses.

3、 Specifications and characteristics

1. Specification: 30mg/tablet, white oval film coated tablet, with "SVCTV" engraved on one side.

2. Appearance: White to off white crystalline solid, slightly soluble in water.

4、 Main components

1. Active ingredient: cabotegravir sodium

2. Accessories: Hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium carboxymethyl starch; The film coating contains hydroxypropyl methylcellulose, polyethylene glycol, and titanium dioxide.

5、 Usage and dosage

1. HIV-1 treatment: Take one tablet (30mg) once a day, along with EDURANT (25mg), with meals.

2. Oral introduction period: at least 28 days.

3. Alternative injection: up to 2 months, for patients who have missed CABENUVA injection.

4. HIV-1 PrEP: once daily, 1 tablet each time, can be taken with or without food.

5. Oral introduction period: at least 28 days.

6. Alternative injection: Used for patients who have missed APRETUDE injection, up to 2 months.

6、 Dose adjustment

1. No dose adjustment is required based on age, gender, weight, kidney function, or mild to moderate liver dysfunction.

2. Insufficient usage data for patients with severe liver dysfunction (Child Pugh C).

7、 Medication precautions

1. Dietary impact: When used for HIV treatment, it should be taken with meals; PrEP can be taken with or without food.

2. Omission treatment: If missed, it should be replenished as soon as possible and medication should continue according to the original plan.

3. Vomiting treatment: If vomiting occurs shortly after taking medication, a doctor should be contacted to assess whether supplementation is necessary.

4. Antacids containing multivalent cations: should be taken at least 2 hours before or 4 hours after taking the medication.

8、 Medication for special populations

1. Pregnant women: Due to limited data, it is recommended to register for pregnancy registration (1-800-258-4263).

2. Breastfeeding period: Cartivavir can enter animal milk, but it is unclear whether it exists in human milk. HIV infected individuals are not recommended to breastfeed.

3. The safety and efficacy of children under 12 years old or weighing less than 35kg have not been established.

4. Elderly people: Data is limited and should be used with caution.

5. Renal insufficiency: mild to severe (CrCl ≥ 15mL/min) does not require dose adjustment; End stage renal disease data is unknown.

6. Liver dysfunction: mild to moderate (Child Pugh A/B) does not require adjustment; Severe (Child Pugh C) data is unknown.

9、 Adverse reactions

1. Common adverse reactions:

Treatment: fatigue, headache, diarrhea, nausea, dizziness, abnormal dreams, anxiety, insomnia, abdominal pain, bloating, fatigue.

PrEP: Headache, diarrhea, nausea, dizziness, upper respiratory tract infection, drowsiness, fatigue, abnormal dreams, abdominal pain.

2. Serious adverse reactions:

Allergic reactions (including Stevens Johnson syndrome).

Hepatotoxicity.

Depressive emotions and suicidal ideation.

Post market report: angioedema, urticaria, SJS/TEN, etc.

10、 Contraindications

1. Individuals allergic to cetuximab.

2. HIV positive individuals (when used for PrEP).

3. Combined with UGT1A1 strong inducers, including carbamazepine, oxcarbazepine, phenobarbital, phenytoin sodium, rifampicin, and rifampicin.

4. When treating HIV, it is prohibited to use CABENUVA in combination with rifampicin.

11、 Drug interactions

1. Avoid co administration with UGT1A1 inducers as it may reduce efficacy.

2. When combined with antacids containing multivalent cations, they should be taken intermittently.

3. When used in combination with rifampicin, the APRETUDE dose (PrEP) needs to be adjusted, but it is prohibited to use it in combination with CABENUVA for treatment.

4. There is no clinically significant interaction with Yiquweilin, Midazolam, oral contraceptives, Lipivirine, etc.

12、 Storage method

1. Storage temperature: below 30 ° C (86 ° F).

2. Avoid contact with children.

13、 Manufacturer

Manufacturer: ViiVHealthcare

Cabotegravirinformation